The study aimed to investigate whether HLA-G antigen is expressed in the kidneys of patients affected by lupus nephritis (LN) and whether its detection in renal biopsies could be adopted as a marker of treatment response and prognosis. Methods: Thirty renal biopsies from patients with LN were selected and analyzed through immunohistochemistry. Laboratory and clinical data were retrospectively collected at baseline, 6 and 12 months and at the latest clinical appointment. A number of patients (63.3%) were treated with rituximab (RTX) þ/À methylprednisolone in the induction phase. The expression of HLA-G in glomeruli, tubules and infiltrating cells was examined and compared between lupus patients who achieved either complete or partial renal response and those who did not respond to treatment. Results: HLA-G staining was observed in the glomeruli of 20 of 30 samples from patients with LN. The expression of the antigen was detected in podocytes, along glomerular capillary walls, on parietal glomerular epithelial cells and within the juxtaglomerular apparatus. Seventy per cent of patients whose glomeruli expressed HLA-G achieved partial or complete response at 6 months and 75% at the latest available follow up compared with 30% and 40%, respectively, of those who did not show any expression. The pattern of staining in tubules and infiltrating cells was highly variable precluding any clinical correlation. Conclusion: This study demonstrates that HLA-G is expressed in renal tissue in LN. Our retrospective data suggest that its expression could correlate with response to treatment. Lupus (2019) 28, 1091-1100.
Introduction
Lupus nephritis (LN) is an organ-threatening complication of systemic lupus erythematosus (SLE), which may develop in 30-60% of patients. The identification of novel molecules involved in the immunopathogenesis of SLE might help to both predict the treatment response and select an adequate treatment. Several studies have looked for a possible role for human leukocyte antigen-G (HLA-G) in SLE. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] HLA-G is a major histocompatibility complex class I antigen encoded on chromosome 6p21.3. It belongs to the non-classical HLA-class I (or class Ib) genes that are characterized by a restricted tissue distribution and limited polymorphism in the coding region. In physiological conditions HLA-G is expressed in cytotrophoblast, cornea, thymus, erythroid and endothelial precursors, T cells, antigen-presenting cells and mesenchymal stem cells (MSCs). autoimmune diseases) the production of the antigen is induced by stimuli such as interferon (IFN)-a, IFN-b and IFN-g, interleukin (IL)-10 and other soluble factors. 16 By alternative splicing of primary transcript, seven isoforms of HLA-G are produced: four membrane-bound (HLA-G1, -G2, -G3, -G4) and three soluble (HLA-G5, -G6, -G7) forms. 17 It has been suggested that the HLA-G gene could be implicated in SLE within the chromosome 6-associated region. 7 The different polymorphisms that influence HLA-G expression have been variously associated with the development of SLE, but the mechanism of these associations remains unclear. 7 A recent study using mouse transplantation models showed that administration of microbeads coated with HLA-G5-b2 m attenuated LN through the inhibition of dendritic cell maturation and B1 cell depletion. 18 HLA-G expression has also been demonstrated in kidneys in a significant proportion of renal cancers, 19 where it is involved in the inhibition of the immune response against cancer cells. It is also detected in renal transplant, 20 where high levels of the antigen are a marker of allograft acceptance. HLA-G also acts as an immunomodulatory molecule at the maternal-fetal interface, preserving tolerance and suppressing inflammation. 21 In this study we investigated the expression of HLA-G in LN and its relationship to treatment response.
Patients and methods

Preliminary analysis
In order to evaluate whether the expression of HLA-G could be detected in renal tissue from biopsies of patients with LN, we conducted a preliminary analysis at the Rheumatology Unit of S. Anna Hospital in Ferrara (Italy), in collaboration with the Department of Medical Sciences, Section of Microbiology and Medical Genetics, and Section of Pathology, University of Ferrara, Italy. We analyzed 19 samples from patients with LN (mainly class IV and V) and 14 samples of unaffected renal tissue obtained from nephrectomies of patients with renal cancer or with traumatic injury.
The specimens were stained manually using an anti-HLA-G primary monoclonal antibody (4H84 Exbio), diluted 1:50, or the isotype-matched IgG1 antibody (Santa Cruz), with the ABC Detection kit (Leica Biosystems, Newcastle, UK). Cytotrophoblast from first trimester human placenta was used as a positive control.
To obtain larger sample size analysis, we subsequently utilized the Bond automated staining system in collaboration with Imperial Lupus Centre, Imperial College Healthcare NHS Trust (ICHNT).
Patients
Thirty kidney biopsies were selected from 30 LN patients enrolled at the Imperial Lupus Centre, ICHNT. Informed consent was obtained according to the Declaration of Helsinki. Ethical approval was obtained from the ICHNT Tissue Bank (NRES approval 12/WA/0196, R14042). All patients met the following inclusion criteria: age >18 years; diagnosis of SLE according to the revised American College of Rheumatology criteria 22 and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE 23 ; and a minimum follow up period of 12 months. The renal samples were obtained from the first biopsy or from biopsies performed at the time of a renal flare (mean SELENA-SLEDAI score 8.3 AE 3.4). LN was classified using the International Society of Nephrology/Renal Pathology Society criteria. 24 Patients whose biopsies showed a high degree of sclerosis and tubular atrophy were excluded from the study. Control renal tissue included sections from non-SLE renal diseases (thin basement membrane nephropathy, TBM). Clinical data was collected at baseline, þ6 and þ12 months after the renal biopsy. We also included data from the most recent clinical assessment. The demographic features of the study population are reported in Table 1 . The treatment criteria for a complete renal response (CR) were defined as follows: urine protein:creatinine ratio (uPCR) 50 mg/mmol in a spot urine and eGFR !60 ml/min; or if 60 ml/min at baseline, has not fallen by >20% compared to baseline. The treatment criteria for a partial renal response (PR) were as follows: eGFR no more than a 20% decrease from the baseline value; and if not nephrotic at baseline (uPCR <300 mg/mmol) 50% improvement in spot uPCR; or if nephrotic at baseline (uPCR >300 mg/mmol), 50% improvement in spot uPCR and uPCR <300 mg/mmol. Non-response was used if neither CR nor PR was achieved.
Immunohistochemistry
Sections (4 micron) were cut from paraffinembedded renal biopsy blocks. The samples were stained with a Bond automated system which utilizes controlled polymerization technology and the Leica-BondTM Polymer Refine Detection system. A heat-induced retrieval system and the same primary monoclonal antibody used for the manual staining (anti-HLA-G, 4H84 Exbio) diluted 1:50 were adopted. Sections of placental tissue were stained as positive controls and an isotype-matched IgG1 (Santa Cruz) antibody was used under similar conditions to control for non-specific staining. 4H84 moAb is able to recognize all b-2-microglobulin-associated HLA-G isoforms, including the G1 and G5 isoform, known to exert the major biological functions. The slides were observed under an Olympus light microscope. With light microscopy, positive staining appears brown. The intensity of staining was graded from 'À' to 'þþþ'.
A score of 'þþþ' represented intensity comparable to the staining of the first-trimester cytotrophoblast sections. A score of 'À' was comparable to the staining of the corresponding negative control using isotype-matched IgG1. The scores 'þ' and 'þþ' were increasing gradations between 'À' and 'þþþ' scores. The degree of interstitial inflammation was scored using a similar semi-quantitative scale. The renal pathologist who interpreted the HLA-G staining results was blinded to the diagnostic categories. The IHC protocol performed in this study used the 4H84 antibody, which is able to recognize all b-2-microglobulin-associated HLA-G isoforms, both soluble and membrane bound. Furthermore, there is a permeabilization step in the protocol that allows staining of not only the membrane-bound HLA-G, but also the soluble isoform that is stored in the cytoplasm endosomes.
Statistical analysis
Results were expressed as mean with standard deviation (SD) or percentages. Categorical variables were compared using Fisher's exact test while comparisons between the median values of two defined patient groups were performed using the MannWhitney U-test. A p < 0.05 value was considered statistically significant. Statistical analysis was performed using GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA).
Results
Preliminary analysis using manual staining on renal biopsy tissue from the Italian cohort Positive staining was observed in tubules and interstitium, but not in glomeruli of 15 LN biopsies, while four samples were completely negative. The higher positivity for HLA-G expression was correlated to the presence of inflammation ( Figure 1 ). We found only one specimen that was HLA-G positive without inflammation. Renal tissue from nephrectomies were all negative, despite a variable degree of inflammation in the tubulointerstitial compartment ( Figure 1 ).
Baseline clinical characteristics and HLA-G expression in glomeruli using automated staining on renal biopsy tissue from the UK cohort Thirty LN samples were stained, and glomerular HLA-G was detected in 20 of them (Table 2 and Figure 2 ). We observed different staining patterns after immunohistochemistry assay: positive staining in the glomerular capillary walls (n ¼ 6); in HLA-G and lupus nephritis V Foschi et al.
podocytes (n ¼ 12); and in both the capillary walls and podocytes (n ¼ 2). Positive HLA-G staining was also observed in parietal glomerular epithelial cells (PECs) of Bowman's capsule in 10 samples. Since PECs can be involved in crescent formation, it was notable that 8 of the 10 samples were proliferative lesions (class III n ¼ 2, class IV n ¼ 2, class IV þ V n ¼ 4), while only 2 were class V LN. Four out of 10 patients had low eGFR (<59 ml/min), and in three the serum creatinine was >110 mmol/l. In five of the 30 samples HLA-G expression was present within the juxtaglomerular apparatus (JGA) (Figure 2(D) ). These five lesions were class V (n ¼ 2), class IIIþV (n ¼ 2) and class III (n ¼ 1). Two samples did not show any staining in other parts of the glomeruli. Two samples had a positive staining in podocytes and one in PECs, but none in the capillary walls. In four patients the renal function was normal, while one patient presented with acute kidney injury. Several studies have demonstrated a correlation between the severity of tubulointerstitial inflammation, kidney damage and risk of renal failure. 27 Since HLA-G can be expressed on inflammatory cells, biopsies with tubulointerstitial cell aggregates were assessed. Although a higher intensity of staining in infiltrating cells was frequently observed in samples with a concurrent diffuse staining in glomeruli and tubules, there were also some sections with rich interstitial inflammatory infiltrates which did not display any expression of HLA-G (Figure 3(B) ).
HLA-G expression in tubules and infiltrating cells
HLA-G expression in other renal biopsies
Nine biopsies from patients with TBM were analyzed. One sample did not contain glomeruli. Three TBM samples showed weak staining in podocytes and three showed moderate staining in the glomerular capillary walls while two did not show any glomerular staining. The expression of the antigen in tubules was variable (data not shown). We found no correlation with the inflammation status.
Correlation of clinical characteristics and glomerular HLA-G staining
We next looked for associations between clinical parameters and glomerular HLA-G staining ( Table 2 ). All the patients in the HLA-G positive group were female, while there were two males in the negative group. Owing to the small number of subjects belonging to ethnic groups other than Caucasians, the influence of ethnicity on HLA-G production was not investigated. No significant differences were seen between the two groups in terms of renal function at the time of the renal biopsy. Although proteinuria was greater in the HLA-G positive group, this did not reach statistical significance. HLA-G expression was detected in the glomeruli of 87.5% (7/8) of patients with pure class V and in 50% of patients with pure proliferative glomerulonephritis (GN) (class III n ¼ 2/4; class IV n ¼ 3/6).
Treatments between the two groups were similar ( Table 2 ). In the HLA-G positive group 12 patients were treated with rituximab (RTX) þ/À methylprednisolone (MP) followed by mycophenolate mofetil (MMF); two patients were treated with RTX þ MP followed, respectively, by methotrexate (MTX) and by hydroxychloroquine (HCQ), two with MMF þ steroids, two with RTX þ MP alone and two with cyclophosphamide (CYC) according to the Eurolupus protocol (one after an infusion reaction to RTX). In the HLA-G negative group three patients were treated with RTX þ/À MP followed by MMF; one patient with RTX þ MP followed by azathioprine (AZA); two with tacrolimus þ MTX or MMF; two with MMF þ steroids; and two with CYC followed by MMF (one after one cycle of RTX). The rituximab regimen was RTX (1 g) and MP (500 mg) on days 1 and 15 28 ; MP was omitted in those cases where concomitant oral prednisolone was given.
At 6 months post-renal biopsy (T6) the percentage of patients classified as non-responders was lower in the HLA-G positive group (30%, n ¼ 6/20) compared with the negative group (70%, n ¼ 7/10, p ¼ 0.05). This difference persisted when data were analyzed at the last available follow up (25% vs 60%, data not shown). Seventy per cent of patients in the HLA-G positive group achieved a partial or complete response at 6 months compared with 30% in the negative group (p ¼ 0.05).
Discussion
Previous studies have shown a potential role of HLA-G in pathogenesis and susceptibility to SLE with contrasting results. 7 This might reflect the different genetic background of the study populations and/or to the lack of a standardized method to measure the soluble levels of the antigen. The role of cell membrane-bound HLA-G in LN is unclear. One mouse study suggested a role of the antigen in suppressing the inflammatory process in kidney, thereby improving renal function. 18 We have demonstrated that HLA-G is expressed in glomeruli in a significant proportion of kidney biopsies from LN patients (66.7%, n ¼ 20/30). Moreover, the antigen can be produced by infiltrating cells and in some specialized structures, such as the JGA. HLA-G staining was detected in endothelial cells of the capillaries, podocytes and PECs of the Bowman's capsule. These cells probably do not express the antigen under physiological conditions, but it is well known that HLA-G expression can be induced by different stimuli. These include hypoxia, indolamine 2,3-dioxygenase (IDO) and some inflammatory mediators that play a central role in LN (IL-10, IFNs). 29 In particular, it has been shown that IFN-a and IFN-g are synthesized by both infiltrating and resident renal cells, including glomerular endothelial cells. 30 Despite its protective effect against rejection and cardiac allograft vasculopathy after heart transplantation, it has been demonstrated that HLA-G is not expressed at baseline in vascular endothelial and smooth muscle cells, but it can be induced by exposure to progesterone. 31 Similarly, we hypothesized that in LN the inflammatory IFN-rich milieu could induce HLA-G production in the glomerular capillary walls. In our study we detected the expression of HLA-G by immunohistochemistry in endothelial cells of 6 out of 30 LN samples: among these samples, only one was a pure class V, while the others were class III (1), IV (1), IIIþV (2) and IVþV (1) . This is consistent with the fact that endothelial cell activation and damage is commonly found in severe proliferative LN where complement activation is localized in the subendothelial space. 32 The HLA-G expression is not modified in control patients, suggesting a different impact of the microenvironment.
Another interesting finding was the detection of HLA-G in the afferent and efferent arterioles in the JGA. This is a specialized structure that plays a central role in the regulation of renal functions and blood pressure through the control of renin release and glomerular hemodynamics. It is possible that this reflects an association between stimuli that regulate the glomerular blood flow and HLA-G expression.
Regarding the epithelial staining, we hypothesized that, similar to endothelial cells, the high level of IFNs and other inflammatory cytokines that characterized the renal environment in LN induced HLA-G expression in podocytes. In a study based on a murine model of necrotizing crescentic glomerulonephritis (NCGN) the authors reported that an in vitro IFN-g treatment stimulated podocyte expression of MHC classes I and II and ICAM-1. This suggested that when podocytes are activated, they participate in the inflammatory process through antigen presentation and expression of adhesion molecules that can promote infiltration of inflammatory cells. 33 In our cohort we have demonstrated the expression of HLA-G in podocytes in 12 of 30 samples of LN. Six of these were pure class V membranous LN, which is mainly characterized by the presence of subepithelial immune deposits and podocyte injury. 34 In 10 of 30 samples the production of HLA-G was also detected in PECs. Emerging data suggest that this cell population is directly involved in the pathogenesis of certain glomerular diseases, such as diabetic nephropathy, crescentic glomerulonephritis and focal segmental glomerulosclerosis where increased cellular activity of PECs has been observed. 35 Different signalling pathways are involved in PEC activation. Activation results in increased proliferation, migration and extracellular matrix production. 36 The role of PECs during glomerular inflammation is still complex. They can proliferate obstructing the urine flow resulting in an impairment in the glomerular function. They can also have a reparative and regenerative role because they are able to migrate from Bowman's capsule to the capillary tuft and replace lost podocytes. 37, 38 In NCGN PECs are involved in cellular crescent formation. Crescents are a typical feature of proliferative GN and are due to the accumulation of PECs, podocytes and infiltrating macrophages within Bowman's space. PECs that form cellular crescents may undergo epithelial-tomesenchymal transition. 39 Since HLA-G can be expressed in both epithelial cells and MSCs, 15 it would be interesting to find out whether it has a role in these processes.
The expression of HLA-G has also been identified in aggregates of infiltrating cells in the periglomerular and peritubular interstitial space. We observed patchy and weak staining in some samples, diffuse and strong in others. This could be due to different cell populations (CD4þ and CD8þ T cells, monocytes, Dendritic cells (DCs)) that form the aggregates and/or to different cytokine patterns produced locally. The precise mechanisms regulating the expression of the antigen in the renal tissue in LN remain to be elucidated. Both genetic (polymorphisms in the promoter and in the 3 0 untranslated region) and non-genetic factors, such as medications (steroids, methotrexate, cyclosporine), may be involved. [40] [41] [42] One limitation of this research was the inability to genotype the samples for HLA-G polymorphisms implicated in HLA-G expression. Further studies are necessary to elucidate the clear mechanisms at the basis of the differential HLA-G expression in LN patients.
Notable, high levels of sHLA-G or of its transcripts in renal tissue are considered a good prognostic factor of renal allograft acceptance, 20 and they seem to have a protective role against the development of LN. In fact, in a recent study investigating the upregulation of T regulatory cells in SLE by MSCs, lower levels of sHLA-G were found in lupus patients with nephritis compared to those without renal involvement. 43 Because of the variability in tubular staining, we focused on correlations between glomerular expression and treatment outcome. Interestingly, 70% of patients who did not show any glomerular HLA-G expression were classified as non-responders at 6 months compared with 30% in the positive group.
The study has limitations with respect to performing a clinicopathological analysis: small sample size, different distribution of proliferative and membranous GN between the two groups, possible influence of medications at baseline and different induction therapies. Due to the retrospective nature of the study, the potential effect of genetic polymorphisms on HLA-G expression and the levels of sHLA-G at the time of renal biopsy were not analyzed. Due to the small number of subjects belonging to different ethnic groups, we did not analyse the impact of ethnicity on HLA-G expression in kidneys and renal response.
To our knowledge there are no previous studies investigating the expression of HLA-G through immunohistochemistry in renal tissue of human LN.
In conclusion, we have demonstrated the diversity and extent of HLA-G renal staining in a group of LN patients. Our retrospective data suggest that glomerular HLA-G staining in LN may associate with treatment outcome. The limited number of patients prevents a significant analysis on the impact of the therapy on HLA-G expression. This explains our decision to concentrate on therapy outcome after 6 months of treatment, independent of the medical regimens followed. Prospective studies with uniform treatment protocols should be performed to determine if glomerular HLA-G staining has prognostic utility in LN. Confirmation of these preliminary data might support use of HLA-G staining during routine automated IHC protocols that are commonly used for LN diagnosis to identify a priori the treatment outcome. This could facilitate a more personalized and efficient therapeutic approach.
